Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGilbert, Richard Een
dc.contributor.authorCox, Allison Jen
dc.contributor.authorWu, L Len
dc.contributor.authorAllen, Terri Jen
dc.contributor.authorHulthen, U Len
dc.contributor.authorJerums, Georgeen
dc.contributor.authorCooper, Mark Een
dc.identifier.citationDiabetes; 47(3): 414-22en
dc.description.abstractTransforming growth factor-beta (TGF-beta) and the renin-angiotensin system (RAS) have both been implicated in the pathogenesis of glomerulosclerosis in diabetic kidney disease. However, tubulointerstitial pathology may also be an important determinant of progressive renal dysfunction in diabetic nephropathy. In the present study, we investigated tubulointerstitial injury, TGF-beta1 expression, and the effect of blocking the RAS by inhibition of ACE. We randomized 36 male SD rats to control and diabetic groups. Diabetes was induced in 24 rats by administration of streptozotocin; 12 diabetic rats were further randomized to receive the ACE inhibitor ramipril (3 mg/l drinking water). At 6 months, experimental diabetes was associated with tubulointerstitial damage, a 70% increase in expression of TGF-beta1 (P < 0.05 vs. control), and a 120% increase in alpha1 (IV) collagen gene expression (P < 0.01 vs. control). In situ hybridization demonstrated a diffuse increase in both TGF-beta1 and alpha1 (IV) collagen mRNA in renal tubules. In addition, intense expression of both transcripts was noted in regions of focal tubular dilatation. Administration of the ACE inhibitor ramipril prevented tubulointerstitial injury and the overexpression of TGF-beta1 and alpha1 (IV) collagen mRNA. Changes in gene expression were accompanied by parallel changes in immunostaining for TGF-beta1 and type IV collagen. The observed beneficial effects of ramipril on the tubulointerstitium in experimental diabetes suggest that this mechanism may contribute to the therapeutic effect of ACE inhibitors in diabetic nephropathy.en
dc.subject.otherAngiotensin-Converting Enzyme Inhibitors.pharmacology.therapeutic useen
dc.subject.otherCohort Studiesen
dc.subject.otherDiabetes Mellitus, Experimental.complicationsen
dc.subject.otherDiabetic Nephropathies.drug therapy.pathologyen
dc.subject.otherGene Expression Regulation, Developmental.geneticsen
dc.subject.otherIn Situ Hybridizationen
dc.subject.otherKidney Tubules.chemistry.drug effects.pathologyen
dc.subject.otherRNA, Messenger.analysis.geneticsen
dc.subject.otherRamipril.pharmacology.therapeutic useen
dc.subject.otherRandom Allocationen
dc.subject.otherRats, Sprague-Dawleyen
dc.subject.otherRenin-Angiotensin System.drug effectsen
dc.subject.otherTransforming Growth Factor beta.biosynthesis.geneticsen
dc.titleExpression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition.en
dc.typeJournal Articleen
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australiaen
dc.type.austinJournal Articleen
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jan 31, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.